Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.

Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.

NEW YORK – AstraZeneca has selected an autologous T-regulator (Treg) cell therapy candidate from Quell Therapeutics' pipeline to advance into preclinical and clinical trials in type 1 diabetes, ...